Condition
Mucopolysaccharidosis IIIB
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Enrolling By Invitation1
Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05368038Enrolling By Invitation
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
NCT06488924Phase 1RecruitingPrimary
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
NCT04655911TerminatedPrimary
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
NCT02324049Phase 1CompletedPrimary
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Showing all 4 trials